On 11 March 2020, the WHO announced the novel coronavirus disease (COVID-19) outbreak to be a global pandemic^([@r1])^. The spread of COVID-19 is becoming unstoppable, and as of 15 May, more than 4 500 000 people have been infected and more than 300 000 people have died ([Fig. 1](#f1){ref-type="fig"})^([@r1])^. The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen of COVID-19. SARS-CoV-2, classified into two β coronaviruses, is an enveloped, positive-sense and single-stranded RNA virus of about 30 kb. The life cycle of the virus with the host comprises mainly five steps as follows: attachment, penetration, biosynthesis, maturation and release. Once SARS-CoV-2 attaches to the host receptors, it penetrates the cells via endocytosis/membrane fusion. Herein, angiotensin-converting enzyme 2 is the entry and functional receptor of SARS-CoV-2. It has been shown that the spike for SARS-CoV-2, structural membrane proteins formed by the *trans*-membrane trimetric glycoprotein protruding from the viral surface, also binds to angiotensin-converting enzyme 2. After the viral contents are released inside the host cells, viral RNA enters the nucleus to replicate. As for the biosynthesis, viral mRNA is used to make viral proteins. The new viral particles are formed in the maturation step and then released^([@r2])^.

Fig. 1.The world map illustrates the total deaths and percentage of severe vitamin D deficiency in countries most commonly affected by COVID-19^([@r1],[@r5]--[@r43])^. Severe vitamin D deficiency (%): (![](S0007114520001749_inline1.jpg)), \>30 (South Arabia, Qatar, Iran, China); (![](S0007114520001749_inline2.jpg)), 20--30 (France, Chile, UK, Portugal); (![](S0007114520001749_inline3.jpg)), 10--20 (Austria, Pakistan, Italy, Poland, Brazil, Israel, Croatia, Romania, Turkey, Germany); (![](S0007114520001749_inline4.jpg)), 5--10 (India, Russia, Switzerland, Canada, Belgium, USA, South Korea, Ireland, Spain); (![](S0007114520001749_inline5.jpg)), \<5 (Greece, Singapore, Mexico, Japan, Ecuador, Australia, Sweden, Malaysia, Norway, Finland, Denmark, Netherlands). Total deaths: (![](S0007114520001749_inline6.jpg)), \>25 000 (USA, UK, Italy, France, Spain); (![](S0007114520001749_inline7.jpg)), 5000--10 000 (Brazil, Belgium, Germany, Iran, The Netherlands, Canada); (![](S0007114520001749_inline8.jpg)), 1000--5000 (China, Mexico, Turkey, Sweden, India, Ecuador, Russia, Peru, Switzerland, Ireland, Portugal, Romania); (![](S0007114520001749_inline9.jpg)), 500--1000 (Poland, Pakistan, Japan, Austria, Denmark); (![](S0007114520001749_inline10.jpg)), \<500 (Chile, Finland, Saudi Arabia, Israel, South Korea, Norway, Greece, Malaysia, Australia, Croatia, Singapore, Qatar).

Angiotensin-converting enzyme 2 plays an important role for the interaction between the classical and non-classical pathway of the renin angiotensin system. The former acts through the angiotensin II type 1 receptors, and its increased activity leads to fibrosis, inflammation and angiogenesis. The latter acts through the Mas receptors and has opposing effects to the angiotensin II type 1 receptors^([@r3])^. Angiotensin-converting enzyme 2 is expressed by the epithelial cells of lungs, intestines, kidneys and blood vessels; therefore, the aforementioned tissues/organs are vulnerable to SARS-CoV-2 infection^([@r4])^. Additionally, activation of the renin angiotensin system is significantly associated with increased morbidity and mortality as in hypertension^([@r3])^.

On the other hand, vitamin D deficiency has also been described as pandemic and a global public health problem, especially in Europe ([Table 1](#tbl1){ref-type="table"})^([@r5]--[@r43])^. Regardless of age, ethnicity and latitude, recent data showed that 40 % of Europeans are vitamin D deficient (25-hydroxyvitamin D (25(OH)D) levels \<50 nmol/l), and 13 % are severely deficient (25(OH)D \< 30 nmol/l)^([@r44])^. According to regression analyses, a quadratic relationship was found between the prevalences of vitamin D deficiency in most commonly affected countries by COVID-19 and the latitudes ([Fig. 2](#f2){ref-type="fig"}). Interestingly, vitamin D deficiency is more common in the subtropical and mid-latitude countries than the tropical and high-latitude countries. Contrary to the expectation, the most commonly affected countries with severe vitamin D deficiency are from the subtropical (Saudi Arabia 46 %; Qatar 46 %; Iran 33·4 %; Chile 26·4 %) and mid-latitude (France 27·3 %; Portugal 21·2 %; Austria 19·3 %) regions. On the other hand, severe vitamin D deficiency was found to be nearly 0 % in some high-latitude countries (e.g. Norway, Finland, Sweden, Denmark and Netherlands). The low prevalences of severe vitamin D deficiencies in high-latitude countries (except for the UK; 23·7 %) can possibly be attributed to the high awareness of vitamin D deficiency, high amount of vitamin D supplementation, food fortification and health policies as well^([@r44])^. Indeed, as the main source of vitamin D is exposure of the skin to sun (UV-B), it has long been supposed that living in a sunny country guarantees sufficient vitamin D levels. However, there is increasing evidence that vitamin D deficiency may have been underestimated/ignored in low latitude, even in tropical countries^([@r45])^.

Table 1.Available data for vitamin D deficiency among older adults in countries most commonly affected by COVID-19Rank[\*](#t1fn1){ref-type="table-fn"}Region/countryLatitude*n*Age (years): mean (±[sd]{.smallcaps}) or range25(OH)D deficiency (%)Reference and year\<25 nmol/l[†](#t1fn2){ref-type="table-fn"}\<50 nmol/lRegion of the Americas1 USAMid latitude (38°)436376±57 (≤30)32Eymundsdottir *et al.* ^([@r5])^ 20206 BrazilSubtropics (23°)90873±514·458·0Lopes *et al.* ^([@r6])^ 201413 PeruTropics (12°)20439±11N/A29·4Pastor *et al.* ^([@r8])^ 201914 CanadaMid latitude (45°)11 3363--797·4 (\<30)36·8Sarafin *et al.* ^([@r7])^ 201518 MexicoTropics (19°)58541±152·043·6Clark *et al.* ^([@r10])^ 201520 ChileSubtropics (33°)686≥6526·4 (\<30)64·9Solis-Urra *et al.* ^([@r11])^ 201921 EcuadorTropics (0°)237471±8N/A21·6Orces *et al.* ^([@r9])^ 2015European region2 SpainMid latitude (41°)312≥8514·4N/AFormiga *et al.* ^([@r12])^ 20143 RussiaHigh latitude (59°)16643--758·0 (\<30)45·7Karonova *et al.* ^([@r17])^ 20164 UKHigh latitude (54°)6004\<5023·7 (\<30)55·3Aspell *et al.* ^([@r14])^ 20195 ItalyMid latitude (41°)264065--9810·621·6Veronese *et al.* ^([@r13])^ 20147 FranceMid latitude (44°)69773±427·355·9Cougnard-Grégoire *et al.* ^([@r15])^ 20158 GermanyHigh latitude (51°)167160--8510·748·6Vetter *et al.* ^([@r16])^ 20209 TurkeyMid latitude (37°)116118--9012·975·5Öztürk *et al.* ^([@r18])^ 201715 BelgiumHigh latitude (50°)69732--537·351·1Hoge *et al.* ^([@r19])^ 201517 NetherlandsHigh latitude (52°)45065--930·02·0Ten Haff *et al.* ^([@r20])^ 201922 SwitzerlandMid latitude (47°)1291≥608·039·2Sakem *et al.* ^([@r21])^ 201323 SwedenHigh latitude (56°)995 (W)80--810·016·0Buchebner *et al.* ^([@r23])^ 201424 PortugalMid latitude (38°)3092≥1821·266·6Duarte *et al.* ^([@r22])^ 202027 IrelandHigh latitude (53°)111818--846·045·0Cashman *et al.* ^([@r24])^ 201328 PolandHigh latitude (51°)577516--9016·065·8Płudowski *et al.* ^([@r26])^ 201630 RomaniaMid latitude (46°)14 05237--6213·252·0Niculescu *et al.* ^([@r27])^ 201732 AustriaMid latitude (47°)16165--8019·364·0Elmadfa *et al.* ^([@r25])^ 201734 DenmarkHigh latitude (56°)340919--720·023·6Cashman *et al.* ^([@r28])^ 201535 NorwayHigh latitude (69°)12 81730--870·318·6Cashman *et al.* ^([@r29])^ 201638 FinlandHigh latitude (64°)410229--770·26·6Cashman *et al.* ^([@r28])^ 201539 GreeceMid latitude (37°)181 (M)20--504·450·3Kassi *et al.* ^([@r30])^ 201540 CroatiaMid latitude (45°)120 (W)61±914·2 (\<30)63·3Laktasic *et al.* ^([@r31])^ 2010Western Pacific Region11 ChinaSubtropics (31°)2180\>6530·6 (\<30)70·3Wei *et al.* ^([@r32])^ 201926 SingaporeTropics (1°)50445--74N/A14·0Robien *et al.* ^([@r33])^ 201331 JapanMid latitude (38°)908440--74N/A53·6Nakamura *et al.* ^([@r34])^ 201533 South KoreaMid latitude (36°)4107 (W)50--796·6 (\<37·5)67·4Shin *et al.* ^([@r35])^ 201536 AustraliaSubtropics (34°)241351±170·922·7Gill *et al.* ^([@r36])^ 201437 MalaysiaTropics (3°)63 (M)≥600·017·5Chin *et al.* ^([@r37])^ 2014Eastern Mediterranean region10 IranSubtropics (30°)370≥3533·461·9Khosravi-Boroujeni *et al.* ^([@r38])^ 201716 Saudi ArabiaSubtropics (24°)347547±1646·076·8Alfawaz *et al.* ^([@r39])^ 201419 PakistanSubtropics (30°)85818--60N/A58·4Mehboobali *et al.* ^([@r40])^ 201525 QatarSubtropics (25°)54749±1346·0N/AEl-Menyar *et al.* ^([@r42])^ 201229 IsraelSubtropics (31°)198 83460 (median)14·449·9Saliba *et al.* ^([@r41])^ 2012South-East Asia region12 IndiaTropics (12°)149≥468·7 (\<30)48·3Mechenro *et al.* ^([@r43])^ 2018*n*, Number; 25(OH)D, 25-hydroxyvitamin D; N/A, not applicable; W, women; M, men.[^1][^2]

Fig. 2.The histogram shows the prevalence of vitamin D deficiency (\<50 nmol/l) and severe deficiency (\<25 nmol/l) among the forty countries most commonly affected by COVID-19. The number above each column represents the country's position in the world ranking concerning the number of total cases of infections. The colour band is a graphical representation of the four main climatic areas in the world. Regression lines show the prevalence of overall (solid black line) and severe (dotted line) vitamin D deficiencies. (![](S0007114520001749_inline11.jpg)), Vitamin D deficiency; (![](S0007114520001749_inline12.jpg)), severe vitamin D deficiency.

The risks for vitamin D deficiency encompass obesity, elderly, lack of proper sun (UV-B) exposure, dark skin, smoking, living with air pollution and the presence of co-morbid diseases such as infection, cancer, CVD, chronic respiratory disease, osteoporosis, sarcopenia and diabetes mellitus^([@r46],[@r47])^. Further, it is known that severe vitamin D deficiency dramatically increases the risk of mortality, infections and many other diseases. As such, it should indisputably be prevented whenever detected/possible^([@r46])^.

Vitamin D hormone has important functions -- including immunomodulant, anti-inflammatory and anti-infective roles^([@r47])^. It acts via monocyte and cell-mediated immunity stimulation, suppression of lymphocyte proliferation, antibody production and cytokine synthesis^([@r48])^. Human lung cells are able to intracellularly convert the inactive 25(OH)D to its active form 1,25(OH)D which reduces proinflammatory cytokines and increases peptides (e.g. the innate antimicrobial peptide cathelicidin)^([@r48])^. Cathelicidin has direct antiviral activity against enveloped respiratory viruses such as hepatitis B, influenza, respiratory syncytial virus and possibly the COVID-19 as well^([@r48])^. Other than the above-mentioned functions, vitamin D has also anti-fibrotic effects. The renin-inhibiting activity and down-regulation of the renin angiotensin system activity seem to be the beneficial effects of vitamin D. Moreover, vitamin D has been shown to suppress angiotensinogen and regulate its expression^([@r49])^.

The distribution of community outbreaks shows seasonal patterns along certain latitude, temperature and humidity, that is, similar to the behaviour of seasonal viral respiratory tract infections. It has been reported that COVID-19 displays significant spread in mid-latitude (35--50° N′) regions and/or in those with an average temperature of 5--11°C and low humidity ([Fig. 1](#f1){ref-type="fig"})^([@r1],[@r50])^. Coronaviruses are very stable at 4°C (viable for up to 3 d) and can survive at −20°C (for up to 2 years)^([@r1])^. Depending on some parameters (e.g. temperature, humidity and sunlight), they can live on different surfaces for a few days. They are thermolabile; decreased sunlight, low temperatures and less humidity seem to be favourable for COVID-19^([@r1])^. Although natural UV (UV-C) from the sunlight may not be strong enough to kill COVID-19, its antimicrobial efficacy has long been shown to inactivate, thus preventing the transmission of airborne-mediated infections such as influenza and tuberculosis^([@r51])^. Further, UV-B from the sun can induce endogenous synthesis of vitamin D in the skin -- being the main source of vitamin D other than the dietary intake or supplementation. These factors might possibly be explanatory as regards the low prevalence of COVID-19 in subtropical and southern countries.

Patients infected with COVID-19 have higher mortality rates if they are older, that is, 8·0 % (70--79 years) and 14·8 % (\>80 years). The similar rates for co-morbid conditions are as 10·5 % (CVD), 7·3 % (diabetes mellitus), 6·3 % (chronic respiratory disease), 6·0 % (hypertension) and 5·6 % (cancer)^([@r52])^. Older adults with any of these co-morbid diseases are at high risk for COVID-19 infection -- especially in the presence of severe vitamin D deficiency^([@r53])^. To this end, since there is positive/strong evidence concerning the effects of vitamin D against viral respiratory infections, it would not be unsound to say that vitamin D supplementation may decrease viral induction and inflammatory genes, and incidence/severity of respiratory tract infections^([@r48])^. In this sense, a meta-analysis of twenty-five randomised controlled trials showed that vitamin D supplementation has a preventive effect against acute respiratory tract infections and that the benefit is higher in those subjects receiving daily or weekly vitamin D without additional bolus doses, and in those having severe vitamin D deficiency at baseline^([@r54])^.

Although vitamin D was primarily recognised for bone metabolism, increasing evidence indicates its proper function for nearly every tissue in the body including brain, heart, lung, muscle, immune system and skin^([@r55])^. Therefore, the treatment of vitamin D deficiency would be vital for several diseases including cardiovascular and neurological disorders, cancers, autoimmune diseases and infections as well^([@r55])^. Likewise, a recent review recommended that in people at risk of influenza/COVID-19 infection, 250 μg/d of vitamin D~3~ for a few weeks (or a month),that is, to rapidly increase the 25(OH)D concentrations and then 125 μg/d in the follow-up can be considered^([@r47])^. The target should be to raise its value above 40--60 ng/ml. Additionally, the authors also suggested higher vitamin D~3~ doses for infected patients with COVID-19. For sure, attention should be paid not to take high calcium supplementation for potential risk of hypercalcaemia while taking high doses of vitamin D~3~. Needless to say, as vitamin D is synthesised mainly in the skin, sun (UV-B) exposure (15--20 min daily) inducing the light pink colour of minimal erythema would be the natural way of production and activation of vitamin D by keratinocytes^([@r55])^.

Accordingly, presenting this paper, we would like to call attention to the possible association between severe vitamin D deficiency and mortality pertaining to COVID-19. Given its rare side effects and relatively wide safety, prophylactic vitamin D supplementation and/or food fortification might reasonably serve as a very convenient and incomparable/invaluable adjuvant therapy for these two worldwide public health problems alike.
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[^1]: The most commonly infected countries and regions with COVID-19 in descending order.

[^2]: Percentages of severe vitamin D deficiency.
